

Raul C Ribeiro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7160372/publications.pdf>

Version: 2024-02-01

190
papers

9,602
citations

50244

46
h-index

40954

93
g-index

193
all docs

193
docs citations

193
times ranked

9178
citing authors

#	ARTICLE	IF	CITATIONS
1	Treating Childhood Acute Lymphoblastic Leukemia without Cranial Irradiation. <i>New England Journal of Medicine</i> , 2009, 360, 2730-2741.	13.9	1,059
2	Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. <i>Lancet Oncology</i> , The, 2010, 11, 543-552.	5.1	514
3	Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIII B at St Jude Children's Research Hospital. <i>Blood</i> , 2004, 104, 2690-2696.	0.6	412
4	Gene expression profiling of pediatric acute myelogenous leukemia. <i>Blood</i> , 2004, 104, 3679-3687.	0.6	404
5	Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2015, 33, 2949-2962.	0.8	277
6	Establishment of a Pediatric Oncology Program and Outcomes of Childhood Acute Lymphoblastic Leukemia in a Resource-Poor Area. <i>JAMA - Journal of the American Medical Association</i> , 2004, 291, 2471.	3.8	256
7	A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer. <i>Nature Structural Biology</i> , 2002, 9, 12-16.	9.7	251
8	Baseline status of paediatric oncology care in ten low-income or mid-income countries receiving My Child Matters support: a descriptive study. <i>Lancet Oncology</i> , The, 2008, 9, 721-729.	5.1	223
9	Comparative Analysis of Different Approaches to Measure Treatment Response in Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2012, 30, 3625-3632.	0.8	188
10	Childhood Adrenocortical Tumors ¹ . <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 2027-2031.	1.8	187
11	Low Leukocyte Counts with Blast Cells in Cerebrospinal Fluid of Children with Newly Diagnosed Acute Lymphoblastic Leukemia. <i>New England Journal of Medicine</i> , 1993, 329, 314-319.	13.9	186
12	Early Intensification of Intrathecal Chemotherapy Virtually Eliminates Central Nervous System Relapse in Children With Acute Lymphoblastic Leukemia. <i>Blood</i> , 1998, 92, 411-415.	0.6	183
13	Traumatic lumbar puncture at diagnosis adversely affects outcome in childhood acute lymphoblastic leukemia. <i>Blood</i> , 2000, 96, 3381-3384.	0.6	180
14	Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study. <i>Lancet Oncology</i> , The, 2015, 16, 465-474.	5.1	177
15	Improved CNS Control of Childhood Acute Lymphoblastic Leukemia Without Cranial Irradiation: St Jude Total Therapy Study 16. <i>Journal of Clinical Oncology</i> , 2019, 37, 3377-3391.	0.8	169
16	Genomic landscape of paediatric adrenocortical tumours. <i>Nature Communications</i> , 2015, 6, 6302.	5.8	166
17	Prevalence and Functional Consequence of TP53 Mutations in Pediatric Adrenocortical Carcinoma: A Children's Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 602-609.	0.8	164
18	Impact of Neonatal Screening and Surveillance for the TP53 R337H Mutation on Early Detection of Childhood Adrenocortical Tumors. <i>Journal of Clinical Oncology</i> , 2013, 31, 2619-2626.	0.8	156

#	ARTICLE	IF	CITATIONS
19	The genomic landscape of pediatric myelodysplastic syndromes. <i>Nature Communications</i> , 2017, 8, 1557.	5.8	143
20	Phase I Pharmacokinetic and Pharmacodynamic Study of the Multikinase Inhibitor Sorafenib in Combination With Clofarabine and Cytarabine in Pediatric Relapsed/Refractory Leukemia. <i>Journal of Clinical Oncology</i> , 2011, 29, 3293-3300.	0.8	142
21	Saving the Children – Improving Childhood Cancer Treatment in Developing Countries. <i>New England Journal of Medicine</i> , 2005, 352, 2158-2160.	13.9	137
22	Clinical features and outcomes of 134 Brazilians with acute promyelocytic leukemia who received ATRA and anthracyclines. <i>Haematologica</i> , 2007, 92, 1431-1432.	1.7	131
23	Sex Differences in Prognosis for Children With Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 1999, 17, 818-818.	0.8	128
24	Biology, clinical characteristics, and management of adrenocortical tumors in children. <i>Pediatric Blood and Cancer</i> , 2005, 45, 265-273.	0.8	127
25	A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome. <i>Blood</i> , 2006, 108, 97-102.	0.6	114
26	The International Pediatric Adrenocortical Tumor Registry initiative: Contributions to clinical, biological, and treatment advances in pediatric adrenocortical tumors. <i>Molecular and Cellular Endocrinology</i> , 2012, 351, 37-43.	1.6	103
27	Pediatric Oncology as the Next Global Child Health Priority: The Need for National Childhood Cancer Strategies in Low- and Middle-Income Countries. <i>PLoS Medicine</i> , 2014, 11, e1001656.	3.9	101
28	Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL. <i>Blood</i> , 2013, 121, 1935-1943.	0.6	96
29	Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination With Fludarabine and Cytarabine, in Pediatric Relapsed or Refractory Acute Leukemia. <i>Journal of Clinical Oncology</i> , 2016, 34, 4094-4101.	0.8	93
30	Determinants of Treatment Abandonment in Childhood Cancer: Results from a Global Survey. <i>PLoS ONE</i> , 2016, 11, e0163090.	1.1	93
31	Magnitude of Treatment Abandonment in Childhood Cancer. <i>PLoS ONE</i> , 2015, 10, e0135230.	1.1	87
32	The My Child Matters programme: effect of public-private partnerships on paediatric cancer care in low-income and middle-income countries. <i>Lancet Oncology</i> , The, 2018, 19, e252-e266.	5.1	84
33	Clinical and biologic features and treatment outcome of children with newly diagnosed acute myeloid leukemia and hyperleukocytosis. <i>Cancer</i> , 2008, 113, 522-529.	2.0	83
34	Pharmacogenetics of Deoxycytidine Kinase: Identification and Characterization of Novel Genetic Variants. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 323, 935-945.	1.3	76
35	Management of APL in Developing Countries: Epidemiology, Challenges and Opportunities for International Collaboration. <i>Hematology American Society of Hematology Education Program</i> , 2006, 2006, 162-168.	0.9	75
36	The magnitude and predictors of abandonment of therapy in paediatric acute leukaemia in middle-income countries: A systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2013, 49, 2555-2564.	1.3	75

#	ARTICLE	IF	CITATIONS
37	Global Pediatric Oncology: Lessons From Partnerships Between High-Income Countries and Low- to Mid-Income Countries. <i>Journal of Clinical Oncology</i> , 2016, 34, 53-61.	0.8	72
38	Germline SAMD9 and SAMD9L mutations are associated with extensive genetic evolution and diverse hematologic outcomes. <i>JCI Insight</i> , 2018, 3, .	2.3	71
39	Clinical Significance of Novel Subtypes of Acute Lymphoblastic Leukemia in the Context of Minimal Residual Diseaseâ€“Directed Therapy. <i>Blood Cancer Discovery</i> , 2021, 2, 326-337.	2.6	71
40	Association of the germline TP53R337H mutation with breast cancer in southern Brazil. <i>BMC Cancer</i> , 2008, 8, 357.	1.1	65
41	Racial/ethnic and socioeconomic disparities in survival among children with acute lymphoblastic leukemia in California, 1988-2011: A population-based observational study. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1819-1825.	0.8	61
42	Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study. <i>Annals of Hematology</i> , 2014, 93, 2001-2010.	0.8	58
43	Effect of body mass index on the outcome of children with acute myeloid leukemia. <i>Cancer</i> , 2012, 118, 5989-5996.	2.0	56
44	Utility of Early Screening Magnetic Resonance Imaging for Extensive Hip Osteonecrosis in Pediatric Patients Treated With Glucocorticoids. <i>Journal of Clinical Oncology</i> , 2015, 33, 610-615.	0.8	56
45	A six-gene leukemic stem cell score identifies high risk pediatric acute myeloid leukemia. <i>Leukemia</i> , 2020, 34, 735-745.	3.3	56
46	Treatment abandonment in childhood acute lymphoblastic leukaemia in China: a retrospective cohort study of the Chinese Childrenâ€™s Cancer Group. <i>Archives of Disease in Childhood</i> , 2019, 104, 522-529.	1.0	55
47	Feasibility, efficacy, and adverse effects of outpatient antibacterial prophylaxis in children with acute myeloid leukemia. <i>Cancer</i> , 2014, 120, 1985-1992.	2.0	53
48	Clinical characteristics of small functioning adrenocortical tumors in children. , 1997, 28, 175-178.		50
49	Genetic Variants in Cytosolic 5â€™-Nucleotidase II Are Associated with Its Expression and Cytarabine Sensitivity in HapMap Cell Lines and in Patients with Acute Myeloid Leukemia. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2011, 339, 9-23.	1.3	50
50	Acute myelogenous leukemia in adolescents and young adults. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27089.	0.8	50
51	A framework to develop adapted treatment regimens to manage pediatric cancer in lowâ€™and middleâ€™income countries: The Pediatric Oncology in Developing Countries (PODC) Committee of the International Pediatric Oncology Society (SIOP). <i>Pediatric Blood and Cancer</i> , 2017, 64, e26879.	0.8	48
52	Vertebral compression fracture as a presenting feature of acute lymphoblastic leukemia in children. <i>Cancer</i> , 1988, 61, 589-592.	2.0	47
53	Effect of race on outcome of white and black children with acute myeloid leukemia: The St. Jude experience. <i>Pediatric Blood and Cancer</i> , 2007, 48, 10-15.	0.8	46
54	Treatment-related mortality in children with acute myeloid leukaemia in Central America: Incidence, timing and predictors. <i>European Journal of Cancer</i> , 2012, 48, 1363-1369.	1.3	41

#	ARTICLE	IF	CITATIONS
55	Reduced dose intensity therapy for pediatric lymphoblastic leukemia: long-term results of the Recife RELLA05 pilot study. <i>Blood</i> , 2020, 135, 1458-1466.	0.6	39
56	Treatment of Pediatric Adrenocortical Carcinoma With Surgery, Retroperitoneal Lymph Node Dissection, and Chemotherapy: The Children's Oncology Group ARAR0332 Protocol. <i>Journal of Clinical Oncology</i> , 2021, 39, 2463-2473.	0.8	38
57	XAF1 as a modifier of p53 function and cancer susceptibility. <i>Science Advances</i> , 2020, 6, eaba3231.	4.7	37
58	Recombinant Urate Oxidase for Prevention of Hyperuricemia and Tumor Lysis Syndrome in Lymphoid Malignancies. <i>Clinical Lymphoma and Myeloma</i> , 2003, 3, 225-232.	2.1	36
59	Disparities in early death and survival in children, adolescents, and young adults with acute promyelocytic leukemia in California. <i>Cancer</i> , 2015, 121, 3990-3997.	2.0	34
60	Decreased relapsed rate and treatment-related mortality contribute to improved outcomes for pediatric acute myeloid leukemia in successive clinical trials. <i>Cancer</i> , 2017, 123, 3791-3798.	2.0	34
61	Clofarabine Can Replace Anthracyclines and Etoposide in Remission Induction Therapy for Childhood Acute Myeloid Leukemia: The AML08 Multicenter, Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 2072-2081.	0.8	34
62	Paratesticular rhabdomyosarcoma: Delayed effects of multimodality therapy and implications for current management. <i>Cancer</i> , 1994, 73, 476-482.	2.0	33
63	Identification of Clinical and Biologic Correlates Associated With Outcome in Children With Adrenocortical Tumors Without Germline TP53 Mutations: A St Jude Adrenocortical Tumor Registry and Children's Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 3956-3963.	0.8	33
64	The Impact of Flt3 Gene Mutations in Acute Promyelocytic Leukemia: A Meta-Analysis. <i>Cancers</i> , 2019, 11, 1311.	1.7	33
65	Interventions targeting absences increase adherence and reduce abandonment of childhood cancer treatment in El Salvador. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1609-1615.	0.8	32
66	Predictors of thrombohemorrhagic early death in children and adolescents with t(15;17)-positive acute promyelocytic leukemia treated with ATRA and chemotherapy. <i>Annals of Hematology</i> , 2017, 96, 1449-1456.	0.8	32
67	A Rare TP53 Mutation Predominant in Ashkenazi Jews Confers Risk of Multiple Cancers. <i>Cancer Research</i> , 2020, 80, 3732-3744.	0.4	32
68	All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies. <i>Annals of Hematology</i> , 2015, 94, 1347-1356.	0.8	31
69	Predictors of outcome and methodological issues in children with acute lymphoblastic leukaemia in El Salvador. <i>European Journal of Cancer</i> , 2010, 46, 3280-3286.	1.3	30
70	Familial predisposition to adrenocortical tumors: Clinical and biological features and management strategies. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2010, 24, 477-490.	2.2	30
71	The treatment of childhood acute lymphoblastic leukemia in Guatemala: Biologic features, treatment hurdles, and results. <i>Cancer</i> , 2017, 123, 436-448.	2.0	30
72	Pharmacokinetics and pharmacodynamics of 21-day continuous oral etoposide in pediatric patients with solid tumors*. <i>Clinical Pharmacology and Therapeutics</i> , 1995, 58, 99-107.	2.3	29

#	ARTICLE	IF	CITATIONS
73	The Role of Leukapheresis in the Current Management of Hyperleukocytosis in Newly Diagnosed Childhood Acute Lymphoblastic Leukemia. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1546-1551.	0.8	29
74	High $\hat{I}^{73}\text{Np73}/\text{TAp73}$ ratio is associated with poor prognosis in acute promyelocytic leukemia. <i>Blood</i> , 2015, 126, 2302-2306.	0.6	28
75	High frequency of loss of heterozygosity at 11p15 and IGF2 overexpression are not related to clinical outcome in childhood adrenocortical tumors positive for the R337H TP53 mutation. <i>Cancer Genetics and Cytogenetics</i> , 2008, 186, 19-24.	1.0	27
76	<i>RRM1</i> and <i>RRM2</i> pharmacogenetics: association with phenotypes in HapMap cell lines and acute myeloid leukemia patients. <i>Pharmacogenomics</i> , 2013, 14, 1449-1466.	0.6	27
77	Contribution of the TP53 R337H mutation to the cancer burden in southern Brazil: Insights from the study of 55 families of children with adrenocortical tumors. <i>Cancer</i> , 2017, 123, 3150-3158.	2.0	26
78	A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML. <i>Nature Communications</i> , 2019, 10, 2189.	5.8	26
79	Integrated epigenetic and genetic analysis identifies markers of prognostic significance in pediatric acute myeloid leukemia. <i>Oncotarget</i> , 2018, 9, 26711-26723.	0.8	26
80	Continuous infusion of interleukin-2 in children with refractory malignancies. <i>Cancer</i> , 1993, 72, 623-628.	2.0	24
81	Splenic rupture in children with hematologic malignancies. , 2000, 88, 480-490.		24
82	Effect of cranial irradiation on sperm concentration of adult survivors of childhood acute lymphoblastic leukemia: a report from the St. Jude Lifetime Cohort Study. <i>Human Reproduction</i> , 2017, 32, 1192-1201.	0.4	24
83	Epstein-Barr virus in pediatric Hodgkin disease: Age and histiotype are more predictive than geographic region. , 1997, 28, 248-254.		23
84	Improving treatment of children with acute lymphoblastic leukemia in developing countries through technology sharing, collaboration and partnerships. <i>Expert Review of Hematology</i> , 2014, 7, 649-657.	1.0	23
85	Prognostic Significance of Major Histocompatibility Complex Class II Expression in Pediatric Adrenocortical Tumors: A St. Jude and Children's Oncology Group Study. <i>Clinical Cancer Research</i> , 2016, 22, 6247-6255.	3.2	22
86	Clinical and biological characteristics of acute lymphocytic leukemia in children with Down syndrome. <i>American Journal of Medical Genetics Part A</i> , 2005, 37, 267-271.	2.4	21
87	Bone mineral density in children with acute lymphoblastic leukemia. <i>Cancer</i> , 2018, 124, 1025-1035.	2.0	21
88	Combining gene mutation with gene expression analysis improves outcome prediction in acute promyelocytic leukemia. <i>Blood</i> , 2019, 134, 951-959.	0.6	21
89	SIOP PODC adapted risk stratification and treatment guidelines: Recommendations for acute myeloid leukemia in resource-limited settings. <i>Pediatric Blood and Cancer</i> , 2023, 70, e28087.	0.8	21
90	Improving Pediatric Cancer Care Disparities Across the United States-Mexico Border: Lessons Learned from a Transcultural Partnership between San Diego and Tijuana. <i>Frontiers in Public Health</i> , 2015, 3, 159.	1.3	20

#	ARTICLE	IF	CITATIONS
91	Predictors of early death and survival among children, adolescents and young adults with acute myeloid leukaemia in California, 1988–2011: a population-based study. <i>British Journal of Haematology</i> , 2016, 173, 292-302.	1.2	20
92	Treatment of acute lymphoblastic leukemia in low- and middle-income countries: Challenges and opportunities. <i>Leukemia and Lymphoma</i> , 2008, 49, 373-376.	0.6	19
93	The Impact of Prospective Telemedicine Implementation in the Management of Childhood Acute Lymphoblastic Leukemia in Recife, Brazil. <i>Telemedicine Journal and E-Health</i> , 2017, 23, 863-867.	1.6	19
94	Survival and risk factors for mortality in pediatric patients with acute myeloid leukemia in a single reference center in low–middle-income country. <i>Annals of Hematology</i> , 2019, 98, 1403-1411.	0.8	17
95	Germline Variants in Phosphodiesterase Genes and Genetic Predisposition to Pediatric Adrenocortical Tumors. <i>Cancers</i> , 2020, 12, 506.	1.7	17
96	Advances in treatment of de-novo pediatric acute myeloid leukemia. <i>Current Opinion in Oncology</i> , 2014, 26, 656-662.	1.1	15
97	Addressing regional disparities in pediatric oncology: Results of a collaborative initiative across the Mexican–North American border. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26387.	0.8	15
98	Management of relapsed and refractory childhood acute promyelocytic leukaemia: recommendations from an international expert panel. <i>British Journal of Haematology</i> , 2016, 175, 588-601.	1.2	14
99	Sorafenib Population Pharmacokinetics and Skin Toxicities in Children and Adolescents with Refractory/Relapsed Leukemia or Solid Tumor Malignancies. <i>Clinical Cancer Research</i> , 2019, 25, 7320-7330.	3.2	14
100	Outcome of pediatric non-Hodgkin lymphoma in Central America: A report of the Association of Pediatric Hematology Oncology of Central America (AHOPCA). <i>Pediatric Blood and Cancer</i> , 2019, 66, e27621.	0.8	14
101	A Phase I Trial of High-Dose Carboplatin and Etoposide with Autologous Marrow Support for Treatment of Stage D Neuroblastoma in First Remission: Use of Marker Genes to Investigate the Biology of Marrow Reconstitution and the Mechanism of Relapse. <i>Human Gene Therapy</i> , 1991, 2, 257-272.	1.4	13
102	Management of Concurrent Pregnancy and Acute Lymphoblastic Malignancy in Teenaged Patients: Two Illustrative Cases and Review of the Literature. <i>Journal of Adolescent and Young Adult Oncology</i> , 2014, 3, 160-175.	0.7	13
103	Prognostic impact of <i>KMT2E</i> transcript levels on outcome of patients with acute promyelocytic leukaemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukaemia study. <i>British Journal of Haematology</i> , 2014, 166, 540-549.	1.2	13
104	Reduced-intensity therapy for pediatric lymphoblastic leukemia: impact of residual disease early in remission induction. <i>Blood</i> , 2021, 137, 20-28.	0.6	13
105	Uncovering the Genomic Landscape in Newly Diagnosed and Relapsed Pediatric Cytogenetically Normal <i>FLT3-ITD</i> AML. <i>Clinical and Translational Science</i> , 2019, 12, 641-647.	1.5	12
106	Safety, pharmacokinetics, and pharmacodynamics of panobinostat in children, adolescents, and young adults with relapsed acute myeloid leukemia. <i>Cancer</i> , 2020, 126, 4800-4805.	2.0	12
107	Genome-wide association analysis identifies SNPs predictive of <i>in vitro</i> leukemic cell sensitivity to cytarabine in pediatric AML. <i>Oncotarget</i> , 2018, 9, 34859-34875.	0.8	12
108	Impact of the Mexican government's system of social protection for health, or <i>Seguro Popular</i> , on pediatric oncology outcomes. <i>Pediatric Blood and Cancer</i> , 2013, 60, 171-172.	0.8	11

#	ARTICLE	IF	CITATIONS
109	Spatial trends in congenital malformations and stream water chemistry in Southern Brazil. <i>Science of the Total Environment</i> , 2019, 650, 1278-1291.	3.9	11
110	Implementing a Childhood Cancer Outcomes Surveillance System Within a Population-Based Cancer Registry. <i>Journal of Global Oncology</i> , 2018, 4, 1-11.	0.5	10
111	Chronic medical conditions and late effects following non-Hodgkin lymphoma in HIV-uninfected and HIV-infected adolescents and young adults: a population-based study. <i>British Journal of Haematology</i> , 2020, 190, 371-384.	1.2	10
112	CPX-351 induces remission in newly diagnosed pediatric secondary myeloid malignancies. <i>Blood Advances</i> , 2022, 6, 521-527.	2.5	10
113	Molecular characterization of <i>KMT2A</i> fusion partner genes in 13 cases of pediatric leukemia with complex or cryptic karyotypes. <i>Hematological Oncology</i> , 2017, 35, 760-768.	0.8	9
114	Adrenocortical tumors associated with the TP53 p.R337H germline mutation can be identified during child-care consultations. <i>Jornal De Pediatria</i> , 2018, 94, 432-439.	0.9	9
115	Ecological principle meets cancer treatment: treating children with acute myeloid leukemia with low-dose chemotherapy. <i>National Science Review</i> , 2019, 6, 469-479.	4.6	9
116	The Common Germline <i>TP53-R337H</i> Mutation Is Hypomorphic and Confers Incomplete Penetrance and Late Tumor Onset in a Mouse Model. <i>Cancer Research</i> , 2021, 81, 2442-2456.	0.4	9
117	Clinical impact of BAALC expression in high-risk acute promyelocytic leukemia. <i>Blood Advances</i> , 2017, 1, 1807-1814.	2.5	8
118	Cavernous transformation of the portal vein in a child with non-Hodgkin's lymphoma. , 1997, 29, 143-145.		7
119	Burkitt lymphoma in African children: A priority for the global health agenda?. <i>Pediatric Blood and Cancer</i> , 2008, 50, 1125-1126.	0.8	7
120	Correlation between selected angiogenic markers and prognosis in pediatric adrenocortical tumors. <i>Journal of Pediatric Surgery</i> , 2015, 50, 1323-1328.	0.8	7
121	Clinical significance of <i>in vivo</i> cytarabine-induced gene expression signature in AML. <i>Leukemia and Lymphoma</i> , 2016, 57, 909-920.	0.6	7
122	Community resources support adherence to treatment for childhood cancer in El Salvador. <i>Journal of Psychosocial Oncology</i> , 2018, 36, 319-332.	0.6	7
123	Molecular approaches identify a cryptic MECOM rearrangement in a child with a rapidly progressive myeloid neoplasm. <i>Cancer Genetics</i> , 2018, 221, 25-30.	0.2	7
124	Comprehensive Ara-C SNP score predicts leukemic cell intracellular ara-CTP levels in pediatric acute myeloid leukemia patients. <i>Pharmacogenomics</i> , 2018, 19, 1101-1110.	0.6	7
125	Reduced SLIT2 is Associated with Increased Cell Proliferation and Arsenic Trioxide Resistance in Acute Promyelocytic Leukemia. <i>Cancers</i> , 2020, 12, 3134.	1.7	7
126	Second Primary Malignancy after Acute Promyelocytic Leukemia: A Population-Based Study. <i>Cancers</i> , 2020, 12, 3610.	1.7	7

#	ARTICLE	IF	CITATIONS
127	Polygenic Ara-C Response Score Identifies Pediatric Patients With Acute Myeloid Leukemia in Need of Chemotherapy Augmentation. <i>Journal of Clinical Oncology</i> , 2022, 40, 772-783.	0.8	7
128	Molecular studies reveal a MLL-MLLT3 gene fusion displaced in a case of childhood acute lymphoblastic leukemia with complex karyotype. <i>Cancer Genetics</i> , 2015, 208, 143-147.	0.2	6
129	DNA Methylation Profiling Reveals Prognostically Significant Groups in Pediatric Adrenocortical Tumors: A Report From the International Pediatric Adrenocortical Tumor Registry. <i>JCO Precision Oncology</i> , 2019, 3, 1-21.	1.5	6
130	Survival after diffuse large B-cell lymphoma among children, adolescents, and young adults in California, 2001-2014: A population-based study. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27559.	0.8	6
131	Whole-joint magnetic resonance imaging to assess osteonecrosis in pediatric patients with acute lymphoblastic lymphoma. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28336.	0.8	6
132	Acute complications. , 2006, , 709-749.		5
133	DNA Methylation Clusters and Their Relation to Cytogenetic Features in Pediatric AML. <i>Cancers</i> , 2020, 12, 3024.	1.7	5
134	NTAL is associated with treatment outcome, cell proliferation and differentiation in acute promyelocytic leukemia. <i>Scientific Reports</i> , 2020, 10, 10315.	1.6	5
135	Pulmonary Manifestations of Hematologic and Oncologic Diseases in Children. <i>Pediatric Clinics of North America</i> , 2021, 68, 61-80.	0.9	5
136	Comprehensive analysis of dose intensity of acute lymphoblastic leukemia chemotherapy. <i>Haematologica</i> , 2022, 107, 371-380.	1.7	5
137	Newborn Screening for the Detection of the TP53 R337H Variant and Surveillance for Early Diagnosis of Pediatric Adrenocortical Tumors: Lessons Learned and Way Forward. <i>Cancers</i> , 2021, 13, 6111.	1.7	5
138	Primary central nervous system lymphoma in a child with acute B-cell lymphoblastic leukaemia: consecutive Epstein-Barr virus-related malignancies. <i>British Journal of Haematology</i> , 1998, 101, 345-348.	1.2	4
139	Minimally myelosuppressive regimen for remission induction in pediatric AML: long-term results of an observational study. <i>Blood Advances</i> , 2021, 5, 1837-1847.	2.5	4
140	Clinical and Functional Significance of TP53 Exon 4-Intron 4 Splice Junction Variants. <i>Molecular Cancer Research</i> , 2022, 20, 207-216.	1.5	4
141	Management of ETV6-ABL1 -positive childhood acute lymphoblastic leukaemia: report of two cases, a literature review and a call for action. <i>British Journal of Haematology</i> , 2021, 193, 197-200.	1.2	3
142	Successful Outcomes of Children Simultaneously Diagnosed with Acute Myeloid Leukemia and Covid-19: The Role of a Mild Chemotherapeutic Induction Regimen. <i>Blood</i> , 2020, 136, 3-4.	0.6	3
143	Clinical Activity, Pharmacokinetics, and Pharmacodynamics of Sorafenib In Pediatric Acute Myeloid Leukemia.. <i>Blood</i> , 2010, 116, 1073-1073.	0.6	3
144	Gene Expression Patterns Associated with Cytarabine Pharmacology and Outcome in Pediatric Acute Myeloid Leukemia.. <i>Blood</i> , 2009, 114, 114-114.	0.6	3

#	ARTICLE	IF	CITATIONS
145	Changes in body mass index, weight, and height in children with acute myeloid leukemia and the associations with outcome. <i>Blood Advances</i> , 2022, 6, 2824-2834.	2.5	3
146	Preclinical and Pilot Study of Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib, with Sorafenib in Acute Myeloid Leukemia and FLT3-Internal Tandem Duplication. <i>Clinical Cancer Research</i> , 2022, 28, 2536-2546.	3.2	3
147	Acute myeloid leukemia. , 2006, , 499-539.		2
148	Molecular and Cytogenetic Studies in a Child with Burkitt Lymphoma and Ataxia-Telangiectasia Syndrome Harboring MYC Overexpression and Partial Trisomy 8. <i>Annals of Laboratory Medicine</i> , 2018, 38, 63-66.	1.2	2
149	Phase 1 study of bendamustine in combination with clofarabine, etoposide, and dexamethasone in pediatric patients with relapsed or refractory hematologic malignancies. <i>Cancer</i> , 2021, 127, 2074-2082.	2.0	2
150	Early mortality and survival improvements for adolescents and young adults with acute promyelocytic leukemia in California: an updated analysis. <i>Haematologica</i> , 2022, 107, 733-736.	1.7	2
151	Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination with Fludarabine and Cytarabine in Pediatric Patients with Relapsed or Refractory AML. <i>Blood</i> , 2015, 126, 1345-1345.	0.6	2
152	Syndrome of Inappropriate Secretion of Anti-Diuretic Hormone in Children with Acute Lymphoblastic Leukemia.. <i>Blood</i> , 2006, 108, 4474-4474.	0.6	2
153	Adrenocortical Tumors in Children With Constitutive Chromosome 11p15 Paternal Uniparental Disomy: Implications for Diagnosis and Treatment. <i>Frontiers in Endocrinology</i> , 2021, 12, 756523.	1.5	2
154	Decitabine combined with minimally myelosuppressive therapy for induction of remission in pediatric high-risk acute myeloid leukemia with chromosome 5q deletion: a report of three cases. <i>International Journal of Hematology</i> , 2022, , .	0.7	2
155	Molecular cytogenetic studies characterizing a novel complex karyotype with an uncommon 5q22 deletion in childhood acute myeloid leukemia. <i>Molecular Cytogenetics</i> , 2015, 8, 62.	0.4	1
156	Predictors of Early Death and Survival Among Children, Adolescents and Young Adults with Acute Myeloid Leukemia in California, 1988-2011: A Population-Based Study. <i>Blood</i> , 2015, 126, 1323-1323.	0.6	1
157	Excellent Outcome for ETV6/RUNX1-Positive Childhood Acute Lymphoblastic Leukemia (ALL) with Contemporary Therapy. <i>Blood</i> , 2010, 116, 495-495.	0.6	1
158	Predictors of Early Death in Childhood Acute Promyelocytic Leukemia: Results of an International Retrospective Study. <i>Blood</i> , 2015, 126, 172-172.	0.6	1
159	The Mutational Profile of Pediatric Therapy-Related Myeloid Neoplasms. <i>Blood</i> , 2018, 132, 2775-2775.	0.6	1
160	Clofarabine-Based Chemotherapy for KMT2Ar Infantile Acute Lymphoblastic Leukemia. <i>Blood</i> , 2021, 138, 3406-3406.	0.6	1
161	Response to the Letter to the Editor from Bleyer. <i>Journal of Adolescent and Young Adult Oncology</i> , 2015, 4, 93-93.	0.7	0
162	Reply to J.-G. Wang et al. <i>Journal of Clinical Oncology</i> , 2021, 39, 3088-3089.	0.8	0

#	ARTICLE	IF	CITATIONS
163	Minimal Residual Diseaseâ€œDirected Therapy for Childhood Acute Myeloid Leukemia: Results of the AML02 Multicenter Trial.. Blood, 2009, 114, 16-16.	0.6	0
164	5'Nucleotidase (NT5C2) Genotype Influences Leukemic Blast Concentration of Ara-CTP in Pediatric Patients with Acute Myeloid Leukemia.. Blood, 2009, 114, 593-593.	0.6	0
165	Pathway Based Pharmacogenomics of Cytarabine In Pediatric Acute Myeloid Leukemia. Blood, 2010, 116, 294-294.	0.6	0
166	Improved Prognosis for Older Adolescents with Acute Lymphoblastic Leukemia. Blood, 2010, 116, 498-498.	0.6	0
167	High-Resolution Genomic Profiling of Adult and Pediatric Core Binding Factor Acute Myeloid Leukemia Reveals New Recurrent Genomic Aberrations. Blood, 2010, 116, 849-849.	0.6	0
168	IDH1 and IDH2 Mutations In Pediatric Acute Myeloid Leukemia. Blood, 2010, 116, 1699-1699.	0.6	0
169	Comparison Between RT-PCR and RQ-PCR for Minimal Residual Disease Detection in Acute Promyelocytic Leukemia: The International Consortium on Acute Promyelocytic Leukemia (IC-APL) Experience,. Blood, 2011, 118, 3552-3552.	0.6	0
170	$^{117}\text{m}\text{Np}73/\text{Tap}73$ Expression Ratio Is Associated with Poor Outcome in Acute Promyelocytic Leukemia,. Blood, 2011, 118, 3536-3536.	0.6	0
171	Aberrant Expression of the MLL5, BAALC, ID1, and WT1 Genes Is Associated with Higher Induction Mortality and Poorer Overall Survival in Acute Promyelocytic Leukemia Patients Treated with ATRA and Anthracycline-Based Chemotherapy: An International Consortium On Acute Promyelocytic Leukemia Study. Blood. 2012, 120, 1407-1407.	0.6	0
172	Cytarabine-Induced Gene Expression Signatures in AML Patients and Its Association with Clinical Outcome.. Blood, 2012, 120, 2470-2470.	0.6	0
173	Novel Genomic Alterations in MCL1 and ARID1A Identified in Pediatric Burkitt Lymphoma Using Targeted High-Throughput Sequencing. Blood, 2012, 120, 899-899.	0.6	0
174	Prognostic Factors For Children With Acute Myeloid Leukemia Who Achieve Minimal Residual Disease-Negative Status After Induction Therapy. Blood, 2013, 122, 490-490.	0.6	0
175	Expression Profiling Of Selected Polycomb Complex Genes In Childhood Acute Myeloid Leukemia Revealed An Overexpression Of EZH2 In Acute Promyelocytic Leukemia. Blood, 2013, 122, 4895-4895.	0.6	0
176	Prognostic Impact Of MLL5 transcript Levels On Outcome Of Patients With Acute Promyelocytic Leukemia Treated With All-Trans Retinoic Acid and Anthracycline-Based Chemotherapy: An International Consortium On Acute Promyelocytic Leukemia Study. Blood, 2013, 122, 2586-2586.	0.6	0
177	Tolerability of 6-Mercaptopurine (6MP) in Patients with Thiopurine Methyltransferase (TPMT) Heterozygosity in the Context of Multi-Agent Therapy for Acute Lymphoblastic Leukemia (ALL). Blood, 2014, 124, 3722-3722.	0.6	0
178	Methylation of DNMT3B Strongly Associates with the Methylome, Cytogenetic Risk Groups, and Prognosis of Pediatric Acute Myeloid Leukemia. Blood, 2015, 126, 2434-2434.	0.6	0
179	Genomic Profiling Identifies Novel Mutations and Fusion Genes in Newly Diagnosed and Relapsed Pediatric FLT3-ITD-Positive AML. Blood, 2016, 128, 2838-2838.	0.6	0
180	Slit-Robo Pathway Is Clinically Relevant and May Represent a Potential Target in Acute Promyelocytic Leukemia. Blood, 2018, 132, 1533-1533.	0.6	0

#	ARTICLE	IF	CITATIONS
181	OR02-1 DNA Methylation Profiling in Pediatric Adrenocortical Tumors Reveals Distinct Methylation Signatures with Prognostic Significance: A Report from the International Pediatric Adrenocortical Tumor Registry. <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.1	0
182	SAT-LB058 Effect of a Genetic Modifier of Cancer Risk in TP53 Mutation Carriers. <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.1	0
183	Clinical and Functional Studies Reveal That TP73 Isoforms Levels Are Associated with Prognosis and RA-Resistance in Acute Promyelocytic Leukemia. <i>Blood</i> , 2019, 134, 2719-2719.	0.6	0
184	Impact of SAMHD1 Pharmacogenetics on Clinical Outcome in Pediatric AML. <i>Blood</i> , 2021, 138, 3429-3429.	0.6	0
185	Liposome-Encapsulated Cytarabine and Daunorubicin (CPX-351) Induces Remission in Newly Diagnosed Pediatric Secondary Myeloid Malignancies. <i>Blood</i> , 2021, 138, 4415-4415.	0.6	0
186	Clinical Features and Cytoreduction Therapy in Children with Newly Diagnosed Acute Myeloid Leukemia and Hyperleukocytosis. <i>Blood</i> , 2021, 138, 2295-2295.	0.6	0
187	Decitabine Combined with Minimally Myelosuppressive Therapy for Induction of Remission of Pediatric High-Risk Acute Myeloid Leukemia with Chromosome 5q Deletion. a Report of Three Cases. <i>Blood</i> , 2021, 138, 4427-4427.	0.6	0
188	Identification of Chemo-Resistant Residual Cell Population in Pediatric AML of Complete Remission By Single Cell RNA Sequencing. <i>Blood</i> , 2020, 136, 25-26.	0.6	0
189	Update on the management of pediatric acute promyelocytic leukemia. <i>Clinical Advances in Hematology and Oncology</i> , 2006, 4, 263-5.	0.3	0
190	Acute leukemia in countries with limited resources. , 2006, , 625-638.		0